{"id":51035,"date":"2022-11-18T15:02:03","date_gmt":"2022-11-18T14:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/"},"modified":"2022-11-18T15:02:03","modified_gmt":"2022-11-18T14:02:03","slug":"idex-corporation-completes-acquisition-of-muon-group","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/","title":{"rendered":"IDEX Corporation Completes Acquisition of Muon Group"},"content":{"rendered":"
\n

NORTHBROOK, Ill.–(BUSINESS WIRE)–IDEX Corporation<\/a> (NYSE:IEX) today announced that it has completed its previously-announced acquisition of micro-precision technology manufacturing company Muon B.V. and its subsidiaries (\u201cMuon Group\u201d).\n<\/p>\n

<\/a><\/p>\n

\nBased in the Netherlands, Muon Group manufactures highly precise flow paths in a variety of materials that enable the movement of various liquids and gases in critical applications for medical technologies, semiconductor, food processing, digital printing and filtration. The group includes LouwersHanique, Veco, Millux, Tecan and Atul, which have critical technical expertise in precision and tolerances for different materials, from metals and glass to plastics and ceramics.\n<\/p>\n

\n\u201cThe Muon Group companies are an IDEX-like collection of businesses, making precise, highly-engineered solutions for mission-critical applications, with a values-based culture that very much matches ours. I\u2019m pleased to welcome the Muon Group team to the IDEX family,\u201d IDEX Chief Executive Officer and President Eric Ashleman said.\n<\/p>\n

\n\u201cIt\u2019s clear that joining a global manufacturing company like IDEX will give us tremendous opportunities to continue scaling up our growth. Becoming part of the IDEX culture and operating model will give us resources, rigor and colleagues that we believe will help us together achieve even greater things,\u201d said Michiel Barendse, Managing Director of Muon Group.\n<\/p>\n

\nMuon Group will report into IDEX\u2019s Health & Science Technology (HST) segment.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include statements regarding the expected benefits of the acquisition of Muon Group. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this press release. The risks and uncertainties include, but are not limited to, the following: the impact of health epidemics and pandemics, including the COVID-19 pandemic, and the impact of related governmental actions, on IDEX\u2019s ability to operate its business and facilities, on its customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars, including Russia’s invasion of Ukraine and the global response to this invasion, which, along with the ongoing effects of the COVID-19 pandemic, could have an adverse impact on IDEX’s business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and IDEX\u2019s results; IDEX\u2019s ability to integrate the Muon Group and to acquire, integrate and operate other acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which IDEX operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain backlogs, including risks affecting component availability, labor inefficiencies and freight logistical challenges; market conditions and material costs; risks related to environmental, social and corporate governance (\u201cESG\u201d) issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the \u201cRisk Factors\u201d section included in IDEX\u2019s most recent annual report on Form 10-K and IDEX\u2019s subsequent quarterly reports filed with the Securities and Exchange Commission (\u201cSEC\u201d) and the other risks discussed in IDEX\u2019s filings with the SEC. The forward-looking statements included here are only made as of the date of this press release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.\n<\/p>\n

\nAbout IDEX<\/strong>\n<\/p>\n

\nIDEX Corporation (NYSE: IEX) makes thousands of products and mission-critical components that improve everyday life all around you. If you enjoy chocolate, it quite possibly passed through a Viking\u00ae internal gear pump at the candy factory. If you were ever in a car accident, emergency workers may have used the Hurst Jaws of Life\u00ae rescue tool to save your life. If your doctor ordered a DNA test to predict your risk of disease or determine a course of treatment, the lab may have used equipment containing components made by IDEX Health & Science. Founded in 1988 with three small, entrepreneurial manufacturing companies, we\u2019re proud to say that we now call over 45 diverse businesses around the world part of the IDEX family. With more than 8,000 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global company with nearly $2.8 billion in annual sales, committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol \u201cIEX\u201d.\n<\/p>\n

\nFor further information on IDEX Corporation and its business units, visit the company\u2019s website at www.idexcorp.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/span>
IDEX Corporation
\n
Allison Lausas
\n
Vice President and Chief Accounting Officer
\n
+1 847-498-7070
\n
investorrelations@idexcorp.com<\/a><\/p>\n

Media Contact<\/span>:
\n
IDEX Corporation
\n
Mark Spencer
\n
+1 847-457-3793
\n
mdspencer@idexcorp.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NORTHBROOK, Ill.–(BUSINESS WIRE)–IDEX Corporation (NYSE:IEX) today announced that it has completed its previously-announced acquisition of micro-precision technology manufacturing company Muon B.V. and its subsidiaries (\u201cMuon Group\u201d). Based in the Netherlands, Muon Group manufactures highly precise flow paths in a variety of materials that enable the movement of various liquids and gases in critical applications for … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51035","6":"format-standard","7":"category-industry"},"yoast_head":"\nIDEX Corporation Completes Acquisition of Muon Group - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IDEX Corporation Completes Acquisition of Muon Group - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NORTHBROOK, Ill.–(BUSINESS WIRE)–IDEX Corporation (NYSE:IEX) today announced that it has completed its previously-announced acquisition of micro-precision technology manufacturing company Muon B.V. and its subsidiaries (\u201cMuon Group\u201d). Based in the Netherlands, Muon Group manufactures highly precise flow paths in a variety of materials that enable the movement of various liquids and gases in critical applications for ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-18T14:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IDEX Corporation Completes Acquisition of Muon Group\",\"datePublished\":\"2022-11-18T14:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/\"},\"wordCount\":921,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117006198\\\/en\\\/1160297\\\/21\\\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/\",\"name\":\"IDEX Corporation Completes Acquisition of Muon Group - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117006198\\\/en\\\/1160297\\\/21\\\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg\",\"datePublished\":\"2022-11-18T14:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117006198\\\/en\\\/1160297\\\/21\\\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221117006198\\\/en\\\/1160297\\\/21\\\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/idex-corporation-completes-acquisition-of-muon-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IDEX Corporation Completes Acquisition of Muon Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IDEX Corporation Completes Acquisition of Muon Group - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/","og_locale":"en_US","og_type":"article","og_title":"IDEX Corporation Completes Acquisition of Muon Group - Pharma Trend","og_description":"NORTHBROOK, Ill.–(BUSINESS WIRE)–IDEX Corporation (NYSE:IEX) today announced that it has completed its previously-announced acquisition of micro-precision technology manufacturing company Muon B.V. and its subsidiaries (\u201cMuon Group\u201d). Based in the Netherlands, Muon Group manufactures highly precise flow paths in a variety of materials that enable the movement of various liquids and gases in critical applications for ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-18T14:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IDEX Corporation Completes Acquisition of Muon Group","datePublished":"2022-11-18T14:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/"},"wordCount":921,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/","url":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/","name":"IDEX Corporation Completes Acquisition of Muon Group - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg","datePublished":"2022-11-18T14:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221117006198\/en\/1160297\/21\/IDEX_Tagline_Blue_Stacked_Square_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/idex-corporation-completes-acquisition-of-muon-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IDEX Corporation Completes Acquisition of Muon Group"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51035"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51035\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}